Navigation Links
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
Date:5/16/2008

ous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.

Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy, says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy.

Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications, says Dr. Nikcevich. Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments.

This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
2. Study suggests blood test can help improve treatment outcomes for breast cancer patients
3. Study takes a step toward better defining fatigue
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Study finds parents use cough medicines on under-2s despite the warnings
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Study Supports Popular HIV Drug Regimen
8. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
9. Study shows that prostate cancer increases the risk of bone fracture
10. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
11. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... very familiar "lub-dub" pattern that speeds up or slows ... itself isn,t as regular as you might think. In ... even at a "constant" heart rateand that variability, doctors ... heart rate variability (HRV) has been found to be ... heart failure and inflammation. For athletes, a drop in ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Medical ... for a three-day conference to discuss brain-related diseases ... injury from concussions and neurodegenerative disorders. , ... director affiliated with a Silverado memory care community ... dedicated expertise in memory care, hosts the annual ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... for delivering,albuterol, a fast-acting bronchial dilator, currently use propellants ... beginning December 31st,2009, or replacement HFA,s. Both propellants are ... at near-supersonic speeds. , ... stream of air by ejecting,the medication from a microfluidic ...
... of,Dermatology (Academy) today issued a statement in response to the ... the,relationship between the use of indoor tanning devices and development ... was submitted pursuant to Section,230 of the Food and Drug ... "The American Academy of Dermatology is pleased that ...
... University Medical Center and 10 other healthcare facilities in the ... from the National Institutes of Health to identify which rehabilitation ... traumatic brain injuries. Rush is the only center in Illinois ... this study is to isolate individual components of the range ...
... a disease that includes the buildup of fatty, ... is the underlying cause of heart attacks and strokes. ... has now demonstrated that a receptor for prostaglandin-E2 plays ... findings, reported this month in Cell Metabolism , ...
... 15 Aurora Health Care announced today that,the ... in southeastern Wisconsin, have chosen to join Aurora Medical Group. ... Lakes radiologists practice chiefly at Aurora hospitals and,clinics. , ... every day contribute to the quality,of the care we provide ...
... based data profiling, In-Stream profiling, data quality and MDM discovery solutions ... Migration Alliance (MMA), joining Microsoft Corp. and other key industry partners ... mainframe onto the Microsoft® platform. , ... Chicago, IL ...
Cached Medicine News:Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:American Academy of Dermatology Issues Statement on FDA Report to Congress About Labeling Information on Indoor Tanning Devices 2Health News:Study to identify best rehabilitation therapies for patients with traumatic brain injuries 2Health News:Prostaglandin receptor key to atherosclerosis development 2Health News:Prostaglandin receptor key to atherosclerosis development 3Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: